Suven Pharmaceuticals Ltd - 543064 - Statement Of Investor Complaints For The Quarter Ended June 2022
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 063630 Name of the Signatory :- K Hanumantha RaoDesignation :- Company Secretary and Compliance Officer Suven Pharmaceuticals Ltd - 543064 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations 2018, please find enclosed herewith the Confirmation Certificates issued by KFin Technologies Limited, Registrar and Share Transfer Agents of the Company, for the quarter ended June 30, 2022. This is for your information and record. Suven Pharmaceuticals Ltd - 543064 - Closure of Trading Window
We wish to inform you that the "Trading Window" for dealing in the securities of the Company will be closed for the Designated Persons, their immediate relatives covered under the said Code of the Company from 1st July, 2022 and the same will remain closed till 48 hours after the declaration of Financial Results for the quarter ending 30th June, 2022, to the public, in terms of the Code of Conduct of the Company under the SEBI (Prohibition of Insider Trading) Regulations, 2015. This is for your information and record. Suven Pharmaceuticals Ltd - 543064 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform that the Company has received intimation from shareholder of the Company, regarding loss of share certificate(s) as details mentioned below. A copy of request letter received from Shareholder is enclosed herewith. Suven Pharmaceuticals Ltd - 543064 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Pursuant to Regulation 30 read with Para-A of Part-A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the transcript of the earnings conference call for the Analyst / Institutional Investor Meeting held on June 1, 2022. The above information has been uploaded on the Company''s website at https://www.suvenpharm.com/index.php/news-events This is for your information and record. Suven Pharmaceuticals Ltd - 543064 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Pursuant to Regulation 30 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and with reference to our Analyst / Institutional Investor Meeting intimation dated May 31, 2022, that audio recording of the Analyst / Institutional Investor Meeting held on June 1, 2022, has been uploaded on the Company''s website at https://www.suvenpharm.com/index.php/news-events This is for your information and record. Suven Pharmaceuticals Ltd - 543064 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
We wish to inform you that senior management team of Suven Pharma is participating in 'B&K Securities Annual Investor Conference - Trinity India 2022' with fund managers and analysts meeting organized in Mumbai by B&K Securities on 1st June, 2022 at 10:00 a.m. IST. Please further note that TRADING WINDOW for dealing in the securities of the company will be closed from June 01, 2022 as per PIT Code of the Company. Trading window will be opened from June 06, 2022. This is for your information and record. Suven Pharmaceuticals Ltd - 543064 - Compliances-Reg.24(A)-Annual Secretarial Compliance
With reference to above subject, please find enclosed herewith the Annual Secretarial Compliance Report issued by Mrs. D. Renuka, Practicing Company Secretary, for the financial year ended 31st March, 2022, under Regulation 24A of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMD1/27/2019 dated 8th February, 2019 Suven Pharmaceuticals Ltd - 543064 - Disclosure Of Related Party Transactions Pursuant To Regulation 23(9) Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015 ("Listing Regulations")
Pursuant to Regulation 23(9) of Listing Regulations, please find enclosed disclosure of related party transactions and balances for the half-year ended 31st March, 2022. This is for your information and record. 